CRINETICS PHARMACEUTICALS IN (CRNX)
US22663K1079 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to CRNX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 59.08. This target is 37.37% above the current price.
CRNX was analyzed by 20 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CRNX.
In the previous month the buy percentage consensus was at a similar level.
CRNX was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-20 | JonesTrading | Maintains | Buy -> Buy |
| 2024-03-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-03-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-13 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-03-13 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-06 | Citigroup | Initiate | Buy |
| 2024-03-04 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-02-29 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-02-29 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-02-29 | Baird | Maintains | Outperform -> Outperform |
| 2024-02-02 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-01-16 | Morgan Stanley | Initiate | Overweight |
| 2023-12-19 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-12-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-04 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-11-20 | JP Morgan | Reiterate | Overweight |
| 2023-09-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-11 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2023-09-11 | Baird | Maintains | Outperform -> Outperform |
| 2023-09-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-31 | Oppenheimer | Initiate | Outperform |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-09 | JMP Securities | Maintains | Market Outperform -> Market Outperform |